Skip to Main Content
Article navigation

Vol. 210, No. 5 | https://doi.org/10.1084/jem.20120950 | April 22, 2013

This article has been retracted at the request of the JEM editors. The article was published on April 22, 2013, and then Fig. 1, E and F, was corrected on January 19, 2017. JEM was notified by the Ohio State University in January 2021 that an investigation by the College of Medicine Investigation Committee (COMIC) determined that the RNU6 data in the original Fig. 1, E and F, as well as in the corrected versions, were falsified. An Expression of Concern was issued on October 3, 2022. After further review, the editors no longer have confidence in the data and are retracting the article. JEM notified all authors for whom contact information could be found but received no response.

Pichiorri
,
F.
,
D.
Palmieri
,
L.
De Luca
,
J.
Consiglio
,
J.
You
,
A.
Rocci
,
T.
Talabere
,
C.
Piovan
,
A.
Lagana
,
L.
Cascione
, et al
.
2017
.
Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
.
J. Exp. Med.
214
:
1557
.
Pichiorri
,
F.
,
D.
Palmieri
,
L.
De Luca
,
J.
Consiglio
,
J.
You
,
A.
Rocci
,
T.
Talabere
,
C.
Piovan
,
A.
Lagana
,
L.
Cascione
, et al
.
2022
.
Expression of Concern: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
.
J. Exp. Med.
219
:e2012095009272022e.
This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

or Create an Account

Close Modal
Close Modal